Intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy is currently the standard of care for the treatment of neovascular age-related macular degeneration. Herein, we describe a mechanism by which some patients who initially show a robust response to treatment may later in their course become refractory to this therapy.
Article InformationCorresponding Author: K. Bailey Freund, MD, Vitreous-Retina-Macula Consultants of New York, 460 Park Ave, 5th Floor, New York, NY 10022 (firstname.lastname@example.org)
Acquisition of data: All authors.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Freund.
Administrative, technical, and material support: Shah.
Conflict of Interest Disclosures: Dr Freund receives research support from Genentech and is a consultant for Genentech and Regeneron.
Funding/Support: This work was supported in part by the Macula Foundation, Inc.